Amrutanjan Health Care 과거 수익 실적
과거 기준 확인 4/6
Amrutanjan Health Care은 연평균 2.4%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 증가했으며, 연간 13.4%였습니다. 매출은 연평균 9.2%의 비율로 증가했습니다. Amrutanjan Health Care의 자기자본이익률은 16%이고 순이익률은 10.9%입니다.
주요 정보
2.4%
수익 성장률
2.5%
EPS 성장률
Pharmaceuticals 산업 성장 | 17.5% |
매출 성장률 | 9.2% |
자기자본 수익률 | 16.0% |
순이익 | 10.9% |
최근 수익 업데이트 | 30 Sep 2024 |
최근 과거 실적 업데이트
Recent updates
Amrutanjan Health Care (NSE:AMRUTANJAN) Is Paying Out A Dividend Of ₹1.00
Nov 19Amrutanjan Health Care's (NSE:AMRUTANJAN) Dividend Will Be ₹2.60
Aug 31Amrutanjan Health Care's (NSE:AMRUTANJAN) Dividend Will Be ₹2.60
Aug 17We Think You Should Be Aware Of Some Concerning Factors In Amrutanjan Health Care's (NSE:AMRUTANJAN) Earnings
May 31Pinning Down Amrutanjan Health Care Limited's (NSE:AMRUTANJAN) P/E Is Difficult Right Now
May 03Amrutanjan Health Care (NSE:AMRUTANJAN) Has Affirmed Its Dividend Of ₹1.00
Feb 12Amrutanjan Health Care (NSE:AMRUTANJAN) Has Announced A Dividend Of ₹2.60
Sep 02Amrutanjan Health Care's (NSE:AMRUTANJAN) Dividend Will Be ₹2.60
Aug 19Amrutanjan Health Care (NSE:AMRUTANJAN) Is Due To Pay A Dividend Of ₹2.60
Aug 05Amrutanjan Health Care (NSE:AMRUTANJAN) Has Announced A Dividend Of ₹1.00
Feb 17Amrutanjan Health Care (NSE:AMRUTANJAN) Will Pay A Dividend Of ₹1.00
Nov 08Amrutanjan Health Care (NSE:AMRUTANJAN) Will Pay A Dividend Of ₹2.60
Aug 18Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 30Should You Be Adding Amrutanjan Health Care (NSE:AMRUTANJAN) To Your Watchlist Today?
Apr 08Introducing Amrutanjan Health Care (NSE:AMRUTANJAN), The Stock That Zoomed 162% In The Last Five Years
Mar 11Trade Alert: The Non-Executive Independent Director Of Amrutanjan Health Care Limited (NSE:AMRUTANJAN), Govindan Raghavan, Has Just Spent ₹72k Buying A Few More Shares
Feb 24Is It Smart To Buy Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Before It Goes Ex-Dividend?
Feb 14Is Amrutanjan Health Care Limited's (NSE:AMRUTANJAN) Latest Stock Performance A Reflection Of Its Financial Health?
Feb 12Is Amrutanjan Health Care Limited (NSE:AMRUTANJAN) A Smart Choice For Dividend Investors?
Jan 30Is There More To The Story Than Amrutanjan Health Care's (NSE:AMRUTANJAN) Earnings Growth?
Jan 17Here's Why I Think Amrutanjan Health Care (NSE:AMRUTANJAN) Is An Interesting Stock
Jan 04What Type Of Shareholders Make Up Amrutanjan Health Care Limited's (NSE:AMRUTANJAN) Share Registry?
Dec 22How Much is Amrutanjan Health Care's (NSE:AMRUTANJAN) CEO Getting Paid?
Dec 09If You Had Bought Amrutanjan Health Care (NSE:AMRUTANJAN) Stock Five Years Ago, You Could Pocket A 106% Gain Today
Nov 26Here's What We Like About Amrutanjan Health Care's (NSE:AMRUTANJAN) Upcoming Dividend
Nov 14Why Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Should Be In Your Dividend Portfolio
Oct 28Are Strong Financial Prospects The Force That Is Driving The Momentum In Amrutanjan Health Care Limited's NSE:AMRUTANJAN) Stock?
Oct 10I Ran A Stock Scan For Earnings Growth And Amrutanjan Health Care (NSE:AMRUTANJAN) Passed With Ease
Sep 22What Percentage Of Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Shares Do Insiders Own?
Sep 01With Amrutanjan Health Care Limited (NSE:AMRUTANJAN) It Looks Like You'll Get What You Pay For
Aug 11Have Insiders Been Selling Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Shares?
Jul 29수익 및 비용 분석
수익 및 비용 분석
Amrutanjan Health Care 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Sep 24 | 4,378 | 475 | 537 | 0 |
30 Jun 24 | 4,271 | 426 | 1,048 | 0 |
31 Mar 24 | 4,214 | 450 | 484 | 0 |
31 Dec 23 | 3,946 | 440 | 398 | 0 |
30 Sep 23 | 3,753 | 373 | 461 | 0 |
30 Jun 23 | 3,865 | 432 | 973 | 0 |
31 Mar 23 | 3,798 | 398 | 493 | 0 |
31 Dec 22 | 3,860 | 418 | 500 | 0 |
30 Sep 22 | 3,990 | 517 | 494 | 0 |
30 Jun 22 | 3,986 | 588 | 1,037 | 0 |
31 Mar 22 | 4,059 | 672 | 505 | 0 |
31 Dec 21 | 3,935 | 627 | 1,211 | 0 |
30 Sep 21 | 3,829 | 631 | 1,159 | 0 |
30 Jun 21 | 3,644 | 668 | 966 | 0 |
31 Mar 21 | 3,330 | 612 | 497 | 0 |
31 Dec 20 | 2,984 | 589 | 763 | 0 |
30 Sep 20 | 2,811 | 474 | 777 | 0 |
30 Jun 20 | 2,635 | 322 | 809 | 0 |
31 Mar 20 | 2,617 | 251 | 834 | 0 |
31 Dec 19 | 2,876 | 314 | 833 | 0 |
30 Sep 19 | 2,751 | 274 | 804 | 0 |
30 Jun 19 | 2,621 | 257 | 750 | 0 |
31 Mar 19 | 2,535 | 250 | 756 | 0 |
31 Dec 18 | 2,406 | 158 | 785 | 0 |
30 Sep 18 | 2,335 | 168 | 762 | 0 |
30 Jun 18 | 2,288 | 201 | 710 | 0 |
31 Mar 18 | 2,203 | 200 | 671 | 0 |
31 Dec 17 | 2,247 | 165 | 722 | 0 |
31 Mar 17 | 2,240 | 211 | 710 | 0 |
31 Mar 16 | 1,867 | 206 | 505 | 0 |
31 Mar 15 | 1,666 | 149 | 468 | 0 |
31 Mar 14 | 1,417 | 124 | 508 | 1 |
양질의 수익: AMRUTANJAN 의 비현금 수입 수준이 높습니다.
이익 마진 증가: AMRUTANJAN 의 현재 순이익 이익률 (10.9%) 작년보다 높습니다 (9.9%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: AMRUTANJAN 의 수입은 지난 5년 동안 매년 2.4% 씩 증가했습니다.
성장 가속화: 지난 1년간 AMRUTANJAN 의 수익 증가율( 27.5% )은 연간 평균( 2.4% 초과합니다. ).
수익 대 산업: 지난 1년간 AMRUTANJAN 수익 증가율( 27.5% )은 Pharmaceuticals 업계 20% 초과했습니다.
자기자본 수익률
높은 ROE: AMRUTANJAN 의 자본 수익률( 16% )은 낮음으로 간주됩니다.